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difference between the median ratios of
each aortic level within all age groups. Was
there any correlation with the recoarctation
or with the hypertension?
Factors influencing the process of reco-
arctation are tubular hypoplasia of the aor-
tic arch, the surgical technique used, infec-
tive aortitis, complete resection of ductal
tissue, suture material, suture technique,
and width of the anastomosis. We do agree
with their conclusion that none of the non-
invasive methods used alone was sufficient
to diagnose aortic recoarctation in every
case, and they should be used as comple-
mentary methods. We would like to add
that magnetic resonance angiography is in-
dicated in all cases of suspected recoarcta-
tion. Currie and colleagues in 19854 state
that maximal catheter peak gradient equals
10.3 plus Doppler gradient.
What was the indication for surgical
intervention? They have seen cases associ-
ated with endocardititis or mesentric enter-
itis preoperatively or postoperatively. What
are the methods of spinal protection they
used to lessen the possibility of paraplegia,
and what is the upper limit in the aortic
clamp time?4
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Reply to the Editor:
In response to Dr Elsayed’s questions, we
would like to clarify that 111 patients had
chest radiography postoperatively. In 57
(51.4%) patients the cardiothoracic ratio
was 0.53 or less, and in 54 patients it was
greater than 0.53. The left ventricular sil-
houette studied by the method was in-
creased in 55 (49.6%) patients. The systolic
ejection fraction (EF%) on echocardiogra-
phy was available postoperatively for 111
patients (mean, 79%  6%; median, 79%;
minimum, 45%; maximum, 92%). The left
ventricular mass was also available for 111
patients (mean, 104.32  28.24 g/m2; me-
dian, 100.00 g/m2; minimum, 50.00 g/m2;
maximum, 220.00 g/m2). The mean left
ventricular diastolic diameter available for
110 patients was 39.7  9.1 mm (median,
38.0 mm; minimum, 20.0 mm; maximum,
63.0 mm). We decided to not include these
variables because 78.8% of the patients had
associated cardiac lesions that could inter-
fere in the results. Furthermore, age and
sex also interfere in the left ventricular
mass, and the sample was not large enough
to include all these variables. In relation to
EF, we observed that in 24 patients with a
mean age at the time of the operation of
14.9  16.4 months (median, 6.8 months;
minimum, 25 days; maximum, 4.6 years),
EF before the operation (mean, 48% 
10%; median, 48%; minimum, 29%; max-
imum, 65%) had a favorable evolution
postoperatively (mean, 79%  5%; mini-
mum, 67%; maximum, 90%).
The aortic ratio median behaved the
same way independently of age at correc-
tion, meaning that it decreased progres-
sively up to the isthmus in each group. This
pattern of behavior was also observed in
normal adult patients1 studied by means of
computed tomography, but the relationship
was always greater than 1.
The recoarctation percentages relative
to surgical techniques were revised and are
correct.
About the surgical indications, 79% of
the patients were symptomatic. The main
symptoms were heart failure with or with-
out cyanosis in small babies (3 of them
were in shock), fatigue, ache in legs, and
headache in older children. In 92 (81.4%)
patients aortic coarctation was considered
severe (gradient at coarctation site 50
mm Hg), in 12 (10.6%) patients it was
moderate, and it could be not classified in 9
(8.0%) patients. Only 1 patient had infec-
tive endocarditis caused by Staphylococcus
aureus after the operation.
The method used for spinal protection
was to decrease the nasoesophageal tem-
perature down to 33°C by means of topical
pleural hypothermia. The upper limit of
aortic clamping was no more than 25 min-
utes.
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Assessing the value of neoadjuvant
chemoradiotherapy and pathologic
downstaging in the treatment of
non–small cell lung cancer
To the Editor:
We read with great interest the article by
Machtay and colleagues,1 which underlines
the feasibility of trimodality treatment
(concurrent chemoradiation followed by
surgical intervention) in the cure of locally
advanced non–small cell lung cancer (LA-
NSCLC) and suggest the use of pathologic
downstaging as a predictor for long-term
survival.
Several studies have explored the com-
bined trimodality treatment: in the ESSEN2
and SWOG3 trials, patients have been
treated with cisplatin plus etoposide (the
same drugs used in this study for 22 pa-
tients) with a similar radiation dose (45
Gy). They reported a rate of acute toxicity
similar to that reported in this article, with
esophageal toxicities as the most frequent.
Esophageal toxicity could correlate with
the adopted radiotherapy volumes, which
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include the bilateral mediastinal nodal re-
gions independently by their involvement.
New data from RTOG trials4 suggest mov-
ing the elective nodal irradiation focalizing
to the gross tumor volume. In our recent
published report,5 exploring a combined
modality treatment with limited irradiation
volume, we have reported a grade 3 esoph-
ageal toxicity rate of 1.1%.
Moreover, surgical-related mortality, as
the authors stated, could be attributed to the
type of operation, pneumonectomy, more
than to induction protocol. Also, data from
neoadjuvant chemotherapy support these
findings.6
Today, lymph node clearance7 and
pathologic downstaging have been pro-
posed as surrogate endpoints for neoadju-
vant treatment in LA-NSCLC. Data from
SAKK and the University of Pennsylvania
agree to group together pathologic stage I
and II (or pN0-1) disease as a predictor of
overall survival and event-free or local re-
currence-free survival. If we look at the
Memorial Sloan Kettering data on 470 pa-
tients treated with neoadjuvant therapy,8
the multivariate analysis shows us a statis-
tically significant difference in term of the
relative rate of deaths between pathologic
stage 0 and stage II to IV disease. No
differences have been reported between
pathologic stage 0 and stage I disease. Ac-
cording to this and our analysis, we share
the hypothesis to use pathologic downstag-
ing to stage 0 to stage I as a direct indicator
of the effectiveness of any multimodality
approach to LA-NSCLC.
Finally, 2 more issues regarding patho-
logic downstaging have to be underlined:
its value as a predictor of distant recurrence
and disease-free survival. In our analysis
we have found a direct effect of downstag-
ing on these parameters that stress the im-
portance of local control on lung cancer,
generally considered a systemic disease,
and the ability of surgical intervention to
achieve an eradication of lung carcinoma.
This last consideration could directly
affect the quality of life of patients accord-
ing to the following syllogism: “no cancer,
no treatment; no treatment, no side ef-
fect”—and no doctors, too.
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Studying the lumen in composite Y
internal thoracic artery–saphenous
vein grafts
To the Editor:
We congratulate Gaudino and colleagues1
for the splendid idea advanced in their
study on composite Y internal thoracic ar-
tery (ITA)–saphenous vein (SV) grafts.
The study of the lumen contributes enor-
mously to the current series of studies de-
scribing the characteristics of composite
grafts. However, we do not share some of
the opinions presented in this article. We
believe that it is not right to use the term
“flow steal” in this specific case, because
the circulatory system is pressurized, is
closed, and responds well to demand. We
do not agree that SV grafts are the worst
conduits. It is already known that SVs in
aorta–left anterior descending coronary ar-
tery grafts are patent in 70% to 80% of the
patients after 10 years. We also believe that
the reduced diameter in distal ITA used to
revascularize coronary arteries that have a
proximal moderate stenosis (70%) is
physiologic and expected. The distal ITA
lumen may be reduced as well when the
supplied coronary artery has a poor runoff.
If there is no flow demand, the ITA graft
will decrease in caliber, because ITA has a
huge ability to adapt itself to flow demand.
It is commonly seen that an ITA supplying
coronaries with proximal severe stenosis
and a good runoff is usually dilated.2 The
fact that SV is less reactive does not com-
promise the coronary irrigation to which it
is anastomosed, because the blood flow in
SV is proportional to the coronary runoff
and not to its diameter. Nevertheless, we
agree with current studies that demonstrate
ITA’s capacity to adapt to flow demand.3
We strongly believe that SV segments do
not jeopardize the composite graft effi-
ciency and have several advantages when
used in such configuration: they are
smaller, they suffer less pressure and shear
stress, and they receive substances pro-
duced by ITA’s endothelium (nitrous ox-
ide, for example). These advantages are
believed to increase SV graft durability.4-6
One must also question results from an
experiment that did not use a group control;
in addition, the small sample does not al-
low for definite conclusions, indicating the
need for more research in this area.
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